UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

Summary

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Eligibility

Inclusion Criteria:

* Age 18-89 years
* Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
* Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time

Exclusion Criteria:

* Unable to provide informed consent
* Previous documented EF =\< 35%
* Currently on BB \>25% target dose
* Uncontrolled hypertension (systolic BP \> 180 at enrollment)
* Has contraindications to all BB or intolerance to metoprolol
* Systolic BP \< 100 or heart rate \<70
* Current cancer requiring active treatment
* Heart transplant or LVAD or expected in the next year
* Life expectancy \< 1 year for any reason
* Dialysis dependence or ESRD
* MI/ PCI/ CABG within 90 days prior to enrollment or planned in the future
* Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
* If PI decides for any reason participation in trial is not in best interest of the patient

Conditions3

Locations1 site

Browse More Trials